Structure-based screening of marine carotenoids: fucoxanthin and its derivatives as potential inhibitors of the SARS-CoV-2 nucleocapsid phosphoprotein
- 28 January 2026
- journal article
- Published by Springer Nature in In Silico Pharmacology
- Vol. 14 (1) , 53
Abstract
Human coronavirus infections, particularly those caused by SARS-CoV-2, remain a significant public health concern. Researchers are actively exploring new antiviral compounds, including those derived from marine natural products. This study investigates fucoxanthin (FX) and its metabolites, fucoxanthinol (FXOH) and amarouciaxanthin A (AXA), as potential inhibitors of the SARS-CoV-2 nucleocapsid phosphoprotein (NP) using molecular docking. Molecular dynamics simulations were performed for 100 ns, along with the reference drug, ribavirin, for comparative purposes. Compared to ribavirin (- 5.870 kcal/mol), FXOH (- 5.662 kcal/mol), AXA (- 5.189 kcal/mol), and FX (- 4.594 kcal/mol), the binding energies were low. RMSD analysis revealed that the NP-ribavirin (1.4-3.8 Å) exhibit a more rigid protein confirmation. In constant, the NP-FX (2.4-4.8 Å), and NP-FXOH (2.5-4.5 Å) showed moderate fluctuations, reflecting the inherent flexibility of the protein. cDFT analysis (HOMO &LUMO) revealed that FX had higher electronic reactivity and charge-transfer capability, whereas FXOH showed greater electronic stability. From these observations, the FX and FXOH remained in the binding site during the MD simulation, and they can be used as an antiviral drug formulation. However, this study is limited to computational prediction, and further in vitro and in vivo investigations are needed to validate the efficacy, safety, and pharmacokinetic properties of ligands.Keywords
This publication has 62 references indexed in Scilit:
- Brown algae biomass for fucoxanthin, fucoidan and alginate; update review on structure, biosynthesis, biological activities and extraction valorisationInternational Journal of Biological Macromolecules, 2024
- Unveiling potential inhibitors targeting the nucleocapsid protein of SARS-CoV-2: Structural insights into their binding sitesInternational Journal of Biological Macromolecules, 2024
- Acetone diethyl ether-based biorefinery process for co-extraction of fucoxanthin, chlorophyll, DHA, and EPA from the diatom Thalassiosira lundianaAlgal Research, 2023
- Health benefits of fucoxanthin in the prevention of chronic diseasesBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2020
- Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein VariantCell, 2020
- Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approachBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
- Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sitesActa Pharmaceutica Sinica B, 2020
- Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in ChinaCell Host & Microbe, 2020
- Structural insights into the mechanism of RNA recognition by the N-terminal RNA-binding domain of the SARS-CoV-2 nucleocapsid phosphoproteinComputational and Structural Biotechnology Journal, 2020
- SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonismVirus Genes, 2010